Safety of Intravenous Autologous Bone Marrow-Derived Mesenchymal Cell Transplantation in 5 Patients With Reduced Left Ventricular Ejection Fraction

Yukihito Sato; Takashi Kuragaichi; Shunsuke Saga; Hiroyuki Nakayama; Tomoe Obata; Mitsumasa Watanabe; Kie Fujikura; Masatoki Watanabe; Ken-ichiro Hata; Hajime Ohgushi

doi:10.1253/circrep.CR-21-0091

This article has now been updated. Please use the final version.

Safety of Intravenous Autologous Bone Marrow-Derived Mesenchymal Cell Transplantation in 5 Patients With Reduced Left Ventricular Ejection Fraction

Yukihito Sato, Takashi Kuragaichi, Shunsuke Saga, Hiroyuki Nakayama, Tomoe Obata, Mitsumasa Watanabe, Kie Fujikura, Masatoki Watanabe, Ken-ichiro Hata, Hajime Ohgushi

Author information

Yukihito Sato
Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center [Japan]
Takashi Kuragaichi
Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center [Japan]
Shunsuke Saga
Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center [Japan]
Hiroyuki Nakayama
Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center [Japan]
Tomoe Obata
Department of Clinical Laboratory, Hyogo Prefectural Amagasaki General Medical Center [Japan]
Mitsumasa Watanabe
Department of Hematology, Hyogo Prefectural Amagasaki General Medical Center [Japan]
Kie Fujikura
Japan Tissue Engineering Co., Ltd. (J-TEC) [Japan]
Masatoki Watanabe
Japan Tissue Engineering Co., Ltd. (J-TEC) [Japan]
Ken-ichiro Hata
Japan Tissue Engineering Co., Ltd. (J-TEC) [Japan]
Hajime Ohgushi
Department of Orthopedic Surgery, Ookuma Hospital [Japan]

Keywords: Heart failure, Mesenchymal cell, Regeneration therapy

JOURNAL OPEN ACCESS FULL-TEXT HTML Advance online publication

Article ID: CR-21-0091

DOI https://doi.org/10.1253/circrep.CR-21-0091

The final version of this article is now available: Vol. 3 (2021), No. 9 pp. 550-554

Details

Abstract

Background:Although intracardiac injection or intracoronary delivery of mesenchymal stem cells (MSCs) has been reported, there have been few studies on the intravenous injection of MSCs, particularly in Japan.

Methods and Results:Five patients with left ventricular ejection fraction (LVEF) ≤45% received 1.0×10⁸MSCs intravenously. The procedure did not induce significant changes in vital signs. One patient had an elevated body temperature after 1 day, but recovered spontaneously. Laboratory tests remained normal for 1 month after cell delivery. Computed tomography was performed after 1–2 years, and there was no evidence of malignancy.

Conclusions:In this pilot study of patients with reduced LVEF, intravenous MSC delivery had no adverse effects.

Corresponding author

Register with J-STAGE for free!